Poseida Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Poseida Therapeutics, Inc.
Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology
The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
Roche Can Extend Lymphoma Lead But Is Still Playing Catch-Up In Myeloma And CAR-T
Roche looks set to keep the upper hand in lymphoma with Polivy and its twin bispecific drugs, but Johnson & Johnson remains the company to beat in multiple myeloma.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- Transposagen Biopharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.